SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-127005
Filing Date
2022-12-14
Accepted
2022-12-14 16:53:53
Documents
13
Period of Report
2022-12-12
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2232682d1_8k.htm   iXBRL 8-K 28390
2 EXHIBIT 10.1 tm2232682d1_ex10-1.htm EX-10.1 40429
  Complete submission text file 0001104659-22-127005.txt   253228

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ruby-20221212.xsd EX-101.SCH 3033
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ruby-20221212_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ruby-20221212_pre.xml EX-101.PRE 22595
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2232682d1_8k_htm.xml XML 3607
Mailing Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139
Business Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139 617-679-9600
Rubius Therapeutics, Inc. (Filer) CIK: 0001709401 (see all company filings)

IRS No.: 042688109 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38586 | Film No.: 221462766
SIC: 2836 Biological Products, (No Diagnostic Substances)